⚕ GalenOps field
←

SITE008-0136

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2022-08-05

AEs
5
Serious
0
Dropout signal
–

Adverse events

severe assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-01 (study day 139); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-13 (study day 151); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-18 (study day 187); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-02-20 (study day 189); relationship: N

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-04-06 (study day 234); relationship: not assessed

Data queries

No data queries.